JP2015529677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529677A5 JP2015529677A5 JP2015531683A JP2015531683A JP2015529677A5 JP 2015529677 A5 JP2015529677 A5 JP 2015529677A5 JP 2015531683 A JP2015531683 A JP 2015531683A JP 2015531683 A JP2015531683 A JP 2015531683A JP 2015529677 A5 JP2015529677 A5 JP 2015529677A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- toxa
- polypeptide
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 52
- 230000002163 immunogen Effects 0.000 claims description 35
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 229960005486 vaccine Drugs 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 206010061819 Disease recurrence Diseases 0.000 claims description 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims description 2
- 101710182223 Toxin B Proteins 0.000 claims description 2
- 101710182532 Toxin a Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000013256 coordination polymer Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1216749.0 | 2012-09-19 | ||
| GB201216748A GB201216748D0 (en) | 2012-09-19 | 2012-09-19 | Methods of treatment |
| GB1216748.2 | 2012-09-19 | ||
| GB201216749A GB201216749D0 (en) | 2012-09-19 | 2012-09-19 | Antigen combinations |
| PCT/IB2013/058673 WO2014045226A1 (en) | 2012-09-19 | 2013-09-19 | Clostridium difficile polypeptides as vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529677A JP2015529677A (ja) | 2015-10-08 |
| JP2015529677A5 true JP2015529677A5 (enExample) | 2016-10-20 |
Family
ID=49725168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531683A Pending JP2015529677A (ja) | 2012-09-19 | 2013-09-19 | ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9932374B2 (enExample) |
| EP (1) | EP2897637A1 (enExample) |
| JP (1) | JP2015529677A (enExample) |
| KR (1) | KR20150056540A (enExample) |
| CN (1) | CN104582722A (enExample) |
| AU (1) | AU2013319821A1 (enExample) |
| BR (1) | BR112015004629A2 (enExample) |
| CA (1) | CA2882620A1 (enExample) |
| IL (1) | IL237172A0 (enExample) |
| MX (1) | MX2015002485A (enExample) |
| RU (1) | RU2015106916A (enExample) |
| SG (1) | SG11201500980WA (enExample) |
| WO (1) | WO2014045226A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391236B (es) | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| GB2525177A (en) * | 2014-04-14 | 2015-10-21 | New Royal Holloway & Bedford | Vaccine |
| ES2870506T3 (es) | 2015-02-19 | 2021-10-27 | Immune Biosolutions Inc | Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3810163A1 (en) | 2018-06-19 | 2021-04-28 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| EP1268774A2 (en) * | 2000-03-21 | 2003-01-02 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
| WO2001094599A1 (en) * | 2000-06-07 | 2001-12-13 | Smittskyddsinstitutet | Gene expression cassette and its use |
| WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| AU2003299527A1 (en) * | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| EP2167119B1 (en) * | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemically modified peptides with improved immunogenicity |
| CA2714720A1 (en) * | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| EP2519257A4 (en) * | 2009-12-02 | 2014-10-15 | Univ Tufts | ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS |
| SG11201402375VA (en) | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
-
2013
- 2013-09-19 BR BR112015004629A patent/BR112015004629A2/pt not_active IP Right Cessation
- 2013-09-19 WO PCT/IB2013/058673 patent/WO2014045226A1/en not_active Ceased
- 2013-09-19 CA CA2882620A patent/CA2882620A1/en active Pending
- 2013-09-19 US US14/425,037 patent/US9932374B2/en active Active
- 2013-09-19 KR KR1020157005022A patent/KR20150056540A/ko not_active Withdrawn
- 2013-09-19 MX MX2015002485A patent/MX2015002485A/es unknown
- 2013-09-19 SG SG11201500980WA patent/SG11201500980WA/en unknown
- 2013-09-19 AU AU2013319821A patent/AU2013319821A1/en not_active Abandoned
- 2013-09-19 JP JP2015531683A patent/JP2015529677A/ja active Pending
- 2013-09-19 RU RU2015106916A patent/RU2015106916A/ru not_active Application Discontinuation
- 2013-09-19 CN CN201380045505.3A patent/CN104582722A/zh active Pending
- 2013-09-19 EP EP13802107.6A patent/EP2897637A1/en active Pending
-
2015
- 2015-02-10 IL IL237172A patent/IL237172A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529677A5 (enExample) | ||
| JP2011250797A5 (enExample) | ||
| JP6505110B2 (ja) | ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用 | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| JP2016504993A5 (enExample) | ||
| JP2015500827A5 (enExample) | ||
| JP2016514713A5 (enExample) | ||
| JP2010516290A5 (enExample) | ||
| HRP20180339T1 (hr) | Imunogeni pripravak | |
| JP2011517938A5 (enExample) | ||
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP2014521605A5 (enExample) | ||
| JP2021042247A (ja) | Ａ群レンサ球菌ワクチン | |
| JP2009520758A5 (enExample) | ||
| JP2013545448A5 (enExample) | ||
| JP2015524802A5 (enExample) | ||
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| Ihan et al. | Odgovor imunološkog sustava na infekciju bakterijom Helicobacter pylori | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| Hedlin et al. | Design and delivery of a cryptic PrPC epitope for induction of PrPSc-specific antibody responses | |
| JP2017521490A5 (enExample) | ||
| Zhang et al. | Protective immunity induced by the vaccination of recombinant Proteus mirabilis OmpA expressed in Pichia pastoris | |
| Ma et al. | Als3‐Th‐cell‐epitopes plus the novel combined adjuvants of CpG, MDP, and FIA synergistically enhanced the immune response of recombinant TRAP derived from Staphylococcus aureus in mice | |
| TW201819402A (zh) | 對抗葡萄球菌感染之疫苗構築體及其用途 | |
| Shaygankho et al. | Passive immunization with anti-FimA egg yolk antibodies (IgYs) mitigate Acinetobacter baumannii pneumonia in mice |